Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Aptevo Therapeutics Inc
(NQ:
APVO
)
32.71
USD
+1.09 (+3.45%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 26, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Aptevo Therapeutics Inc
< Previous
1
2
3
4
Next >
Aptevo Confirms Receipt of Nominations and Proposal Notice
February 09, 2021
From
ACCESSWIRE
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
January 11, 2021
From
ACCESSWIRE
Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442
December 02, 2020
From
ACCESSWIRE
Aptevo Confirms Receipt of Unsolicited Indication of Interest
November 19, 2020
From
ACCESSWIRE
Thinking about buying stock in Aptevo Therapeutics, Electrameccanica Vehicles, AstraZeneca, Corcept Therapeutics, or 22nd Century Group?
November 19, 2020
InvestorsObserver issues critical PriceWatch Alerts for APVO, SOLO, AZN, CORT, and XXII.
From
PR Newswire
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
November 16, 2020
Alligator Bioscience ("Alligator") (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy and Aptevo Therapeutics Inc. ("Aptevo")...
From
PR Newswire
Medexus Reaches 50% Enrollment in IXINITY® Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Patients
November 16, 2020
From
GlobeNewswire News Releases
Aptevo Therapeutics and Alligator Bioscience Advancing the Bispecific 4-1BBx5T4 Antibody ALG.APV-527 Into Phase 1 Clinical Development
November 16, 2020
From
ACCESSWIRE
Thinking about buying stock in Surface Oncology, Northern Oil & Gas, Co-Diagnostics, Howmet Aerospace, or Aptevo Therapeutics?
November 11, 2020
InvestorsObserver issues critical PriceWatch Alerts for SURF, NOG, CODX, HWM, and APVO.
From
PR Newswire
Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update
November 10, 2020
From
ACCESSWIRE
Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting
November 09, 2020
From
ACCESSWIRE
Biotech Brief: Breast Cancer Drug Market Could Exceed $38 Billion By 2025
November 09, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biotech Brief: Breast Cancer Drug Market Could Exceed $38 Billion By 2025
November 09, 2020
Financialnewsmedia.com News Commentary
From
PR Newswire
Thinking about buying stock in American Airlines, Carnival Corp, Pfizer, Aptevo Therapeutics, or Aurora Cannabis?
November 09, 2020
InvestorsObserver issues critical PriceWatch Alerts for AAL, CCL, PFE, APVO, and ACB.
From
PR Newswire
Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
November 09, 2020
From
ACCESSWIRE
Aptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan
November 08, 2020
From
ACCESSWIRE
Thinking about buying stock in Sundial Growers, Aptevo Therapeutics, Aphria Inc, Medifast, or Freeport-McMoRan?
November 03, 2020
InvestorsObserver issues critical PriceWatch Alerts for SNDL, APVO, APHA, MED, and FCX.
From
PR Newswire
Aptevo Therapeutics Announces First Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
November 03, 2020
From
ACCESSWIRE
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
September 01, 2020
From
ACCESSWIRE
Aptevo Therapeutics Reports Second Quarter 2020 Financial Results
August 14, 2020
From
ACCESSWIRE
Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust
August 06, 2020
From
ACCESSWIRE
Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones
July 21, 2020
From
ACCESSWIRE
Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale
June 29, 2020
From
ACCESSWIRE
Thinking about buying stock in Ekso Bionics, Apple Inc, GNC Holdings, Microsoft Corp, or Aptevo Therapeutics?
June 25, 2020
InvestorsObserver issues critical PriceWatch Alerts for EKSO, AAPL, GNC, MSFT, and APVO.
From
PR Newswire
Aptevo Therapeutics to receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar
June 25, 2020
From
ACCESSWIRE
Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit
June 10, 2020
- New Preclinical Data Show That ALG.APV-527 has Potential for a Favorable Safety Profile
From
PR Newswire
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit
June 10, 2020
From
ACCESSWIRE
Aptevo Therapeutics Reports First Quarter 2020 Financial Results
May 13, 2020
From
ACCESSWIRE
Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements
April 14, 2020
From
ACCESSWIRE
Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update
March 25, 2020
From
ACCESSWIRE
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.